In The Press November 18, 2019

Getting Biosimilars to Market - Patent and Antitrust Perspectives

Goodwin partner Elaine Herrmann Blais, who focuses her practice on intellectual property litigation and particularly with respect to patent litigation for the life sciences industry, participated in a virtual panel discussion around the considerable commercial hurdles that biosimilars face from both an antitrust and patent perspective. Read the published commentary here.